Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/2/2024 | $10.00 | Buy | Guggenheim |
| 7/3/2024 | $7.00 | Overweight | Morgan Stanley |
| 3/14/2024 | $13.00 | Sector Outperform | Scotiabank |
| 12/5/2023 | $3.00 | Overweight | KeyBanc Capital Markets |
| 5/4/2023 | $4.00 | Buy | H.C. Wainwright |
| 8/12/2022 | Overweight → Underweight | JP Morgan | |
| 7/18/2022 | $8.00 | Buy | Truist |
| 3/2/2022 | Market Perform | Cowen |
4 - Absci Corp (0001672688) (Issuer)
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City. The program will begin at 9:00 a.m. Eastern Time and feature presentations from members of Absci's leadership team as well as guest speakers, followed by an interactive Q&A session. The program is expected to conclude at approximately 12:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of Absci's R&D Day on the company's investor relations website at: investors.absci.com. About Absci Absci is a data-first genera
VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) a data-first generative AI drug creation company, and Twist Bioscience Corporation (NASDAQ:TWST) a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today unveiled a collaboration to design a novel therapeutic using generative AI. "Bringing together two leaders in biotechnology innovation represents an opportunity to accelerate pharmaceutical R&D," said Absci Founder & CEO Sean McClain. "We are excited to strengthen our relationship with Twist and leverage the power of our shared platforms to bring better bio
VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. Truist Securities BioPharma Symposium (New York, NY)Hosting 1x1 meetings on Thursday, November 7 Guggenheim Securities Inaugural Healthcare Innovation Conference (Boston, MA)Fireside chat on Monday, November 11 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time, and hosting 1x1 meetings UBS Global Healthcare Conference (Rancho Palos Verdes, CA)Fireside chat on Wednesday, November 13 at 10:15 a.m. Eastern Time / 7:15 a.m. Pacific Time, and hosti
Keybanc analyst Scott Schoenhaus maintains Absci (NASDAQ:ABSI) with a Overweight and lowers the price target from $8 to $6.
U.S. stocks were higher, with the Dow Jones index surging around 200 points on Monday. Shares of Corning Incorporated (NYSE:GLW) rose sharply during Monday's session after the company increased its second-quarter core sales guidance. The company said it now projects core sales to be approximately $3.6 billion (vs. consensus of $3.41 billion), an increase from the previous guidance of $3.4 billion. Core EPS is expected to reach the high end of, or slightly exceed, the management's guided range of $0.42 to $0.46 (vs. estimate of $0.45). Corning shares jumped 9.4% to $42.05 on Monday. Here are some other big stocks recording gains in today’s session. Morphic Holding, Inc. (NASDA
Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca. In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e
VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success. During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a
VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a generative AI drug creation company, today announced Meta Connectivity VP Dan Rabinovitsj as the newest member of its Board of Directors. With three decades of leadership in scaling technologies, innovating business models and growing companies, Mr. Rabinovitsj will provide strategic insights as Absci continues to scale its unprecedented combination of AI and wet lab capabilities to help create better biologics for patients, faster. "Absci has impressed me with their technology and data, together which have the potential to turn Absci's bold vision into reality: to create therapeutics at a
SC 13D/A - Absci Corp (0001672688) (Subject)
SC 13G/A - Absci Corp (0001672688) (Subject)
SC 13G - Absci Corp (0001672688) (Subject)
8-K - Absci Corp (0001672688) (Filer)
10-Q - Absci Corp (0001672688) (Filer)
8-K - Absci Corp (0001672688) (Filer)
VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the
Released results from non-human primate studies for ABS-101, demonstrating 2-3x extended half-life as compared to antibodies in clinical development Entered into collaboration with Memorial Sloan Kettering Cancer Center to co-develop up to six novel oncology therapeutics VANCOUVER, Wash. and NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended June 30, 2024. "Our recent achievements demonstrate solid execution across all aspects of our business, as we continue to progress internal and partnered programs according to plan," said Sean McClain, Foun
VANCOUVER, Wash. and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the second quarter after market close on Wednesday, August 14, 2024. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
Guggenheim initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $10.00
Morgan Stanley initiated coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00
Scotiabank initiated coverage of Absci Corporation with a rating of Sector Outperform and set a new price target of $13.00